- Novamind (NM) is set to present at the Benzinga Cannabis Capital Conference on February 25-26, 2021
- The company’s Chief Medical Officer will participate in a panel discussion on psychedelics
- The company’s CEO will share Novamind’s vision for scaling access to psychedelic medicine and advancing clinical research
- Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats and clinical research sites
- Novamind (NM) is trading steady at C$2.15
Novamind (NM) is set to present at the Benzinga Cannabis Capital Conference on February 25-26, 2021.
Benzinga offers an interactive forum of live presentations from top CEOs, investors and leaders in the cannabis space.
On Friday, February 26, 2021 at 1:30 pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the company’s vision for scaling access to psychedelic medicine and advancing clinical research.
On Friday, at 1:50 pm EST, the company’s Chief Medical Officer, Reid Robison, will participate in a panel discussion on psychedelics.
“We are excited to connect with investors who share our belief that innovative mental health therapies are disrupting the current standard of care in mental health,” said Conforti. “I look forward to this opportunity to share Novamind’s approach to mental healthcare and clinical research in psychedelic medicine.”
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.
Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics. It also operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.
Novamind (NM) is trading steady at C$2.15 as of 1:36 pm EST.
